Johnson & Johnson (JNJ) Stock on December 10, 2025: Pipeline Breakthroughs, Talc Risks and What Analysts Expect Next

Johnson & Johnson is trading near fresh highs as investors weigh powerful growth drivers in oncology and immunology against a still‑messy overhang from talc litigation.

Financial Forecasts · NYSE:JNJ · Pharmaceuticals · Stock Market
Novo Nordisk A/S (NVO) Stock Today: Akero Deal, GLP‑1 Competition and Analyst Downgrades – What 10 December 2025 Means for Investors

Novo Nordisk A/S (NVO) Stock Today: Akero Deal, GLP‑1 Competition and Analyst Downgrades – What 10 December 2025 Means for Investors

American depositary shares of Novo Nordisk A/S recently traded around $48 in New York, up roughly 3–4% intraday, with the session range hovering between about $47 and $48.3. That rebound comes after months of brutal underperformance and a barrage of fresh news: an M&A deal closing, obesity pipeline updates, an important downgrade from Argus, and increasingly loud questions about whether the GLP‑1 champion can hold its crown.
10 December 2025
··
Teva Pharmaceutical Industries (TEVA) Stock: FDA Filing, Analyst Upgrades and 2026–27 Outlook on December 10, 2025

Teva Pharmaceutical Industries (TEVA) Stock: FDA Filing, Analyst Upgrades and 2026–27 Outlook on December 10, 2025

Teva Pharmaceutical Industries Limited is trading around its 52‑week highs as a wave of fresh news hits the stock: a new U.S. FDA filing for a once‑monthly schizophrenia drug, a string of bullish analyst upgrades, stronger long‑term cash‑flow guidance and notable institutional activity. At around $29 per share, Teva now carries a market capitalization of roughly $32–33 billion, with a 12‑month trading range of approximately $12.5 to just over $29.MarketBeat+2MarketBeat+2
10 December 2025
··
Eli Lilly (LLY) Stock Near $1 Trillion: Zepbound Price Cuts, New $6B Plant and 2026 Dividend Hike – Is It Still a Buy?

Eli Lilly (LLY) Stock Near $1 Trillion: Zepbound Price Cuts, New $6B Plant and 2026 Dividend Hike – Is It Still a Buy?

As of mid‑day trading on December 10, 2025, Eli Lilly is changing hands at around $980 per share, down slightly on the day and just below its recent all‑time high above $1,050. That price values Lilly at roughly $930–$1,000+ billion in market cap, depending on intraday moves, placing it in the same league as mega‑cap tech giants and making it the first healthcare company ever to cross the $1 trillion mark. Reuters
10 December 2025
··
Biodexa Pharmaceuticals (NASDAQ: BDRX) Stock on December 10, 2025: Violent Rally, Phase 3 FAP Progress and What 2026 Might Hold

Biodexa Pharmaceuticals (NASDAQ: BDRX) Stock on December 10, 2025: Violent Rally, Phase 3 FAP Progress and What 2026 Might Hold

Biodexa Pharmaceuticals plc has turned into one of the most volatile biotech tickers of late 2025. After a sharp multi‑day surge driven by retail trading interest and momentum headlines, the stock has whipsawed back down, even as the company advances a pivotal Phase 3 trial in a rare inherited cancer syndrome and lines up multiple new financing options. StockInvest+2MarketWatch+2
10 December 2025
··
Eli Lilly’s $6 Billion Huntsville Plant: 450 High‑Paying Jobs, GLP‑1 Drug Boom and Alabama’s Biggest Industrial Bet

Eli Lilly’s $6 Billion Huntsville Plant: 450 High‑Paying Jobs, GLP‑1 Drug Boom and Alabama’s Biggest Industrial Bet

Eli Lilly and Company will invest more than $6 billion in a new advanced pharmaceutical manufacturing campus in Huntsville, Alabama, creating 450 high‑value permanent jobs and an estimated 3,000 construction jobs in what state leaders are calling the largest initial private industrial investment in Alabama history. City of Huntsville+2governor.alabama.gov+2
10 December 2025
·
Arrowhead Pharmaceuticals (ARWR) Stock Soars on First FDA Approval, Novartis Deal and New Alzheimer’s Trial

Arrowhead Pharmaceuticals (ARWR) Stock Soars on First FDA Approval, Novartis Deal and New Alzheimer’s Trial

Arrowhead Pharmaceuticals, Inc. is ending 2025 in rare biotech air. The RNA interference specialist has secured its first U.S. drug approval, locked in a multibillion‑dollar licensing deal with Novartis, and just dosed the first subjects in a new Alzheimer’s disease trial — all while its share price hovers near record highs. Arrowhead Pharmaceuticals, Inc.+2Arrowhead Pharmaceuticals+2
9 December 2025
··
Eli Lilly (LLY) Stock After Hours on December 8, 2025: China Mounjaro Win, Dividend Hike and What to Watch Before Tuesday’s Open

Eli Lilly (LLY) Stock After Hours on December 8, 2025: China Mounjaro Win, Dividend Hike and What to Watch Before Tuesday’s Open

Eli Lilly and Company spent Monday, December 8, 2025, digesting a wave of news: a major reimbursement win for Mounjaro in China, a 15% dividend hike, new leukemia drug data, and the return of Nobel laureate Carolyn Bertozzi to its board. At the same time, intensifying competition and price cuts in the weight‑loss drug market kept pressure on the stock.
9 December 2025
······
Pfizer (PFE) Stock Today: Hemophilia Breakthrough, Metsera Deal and AI Cost Cuts – Price, Forecast and News for December 8, 2025

Pfizer (PFE) Stock Today: Hemophilia Breakthrough, Metsera Deal and AI Cost Cuts – Price, Forecast and News for December 8, 2025

Pfizer Inc. is back in focus on December 8, 2025, as investors digest fresh clinical data in hemophilia, big strategic bets in obesity drugs, and an aggressive, AI‑driven cost‑cutting program – all while the stock continues to trade at a high dividend yield and a discount to many Big Pharma peers.
8 December 2025
···
Nurix Therapeutics (NRIX) Stock Soars on ASH 2025 Trial Data: Latest News, Analyst Forecasts and Outlook as of December 8, 2025

Nurix Therapeutics (NRIX) Stock Soars on ASH 2025 Trial Data: Latest News, Analyst Forecasts and Outlook as of December 8, 2025

Nurix Therapeutics, Inc. is back in the spotlight. On December 8, 2025, the biotech stock surged roughly 20% intraday after the company released new Phase 1 data for its Bruton’s tyrosine kinase degrader bexobrutideg in blood cancers at the American Society of Hematology Annual Meeting and scheduled a corporate webcast for this evening. MarketBeat+3GlobeNewswire+3GlobeNewswire+3
8 December 2025
··
Merck (MRK) Stock Today – December 8, 2025: Pipeline Bets, Cidara Deal and Vaccine Policy Risks

Merck (MRK) Stock Today – December 8, 2025: Pipeline Bets, Cidara Deal and Vaccine Policy Risks

Merck & Co., Inc. is back in the spotlight. As of the afternoon of December 8, 2025, Merck shares trade around $98–99, down about 1% on the day and modestly below their recent 52‑week high of $105.84 reached in late November. That pullback comes after a powerful rebound from a May low near $76, driven by excitement over new cardiovascular and respiratory drugs, plus a $9.2 billion flu‑drug acquisition — even as investors remain focused on the looming 2028 patent cliff for Keytruda and fresh regulatory headwinds.Finviz+2Reuters+2
8 December 2025
··
Recursion Pharmaceuticals (RXRX) Stock Jumps on Positive FAP Trial Data: Latest News, AI Drug Discovery Outlook and Analyst Forecasts

Recursion Pharmaceuticals (RXRX) Stock Jumps on Positive FAP Trial Data: Latest News, AI Drug Discovery Outlook and Analyst Forecasts

Recursion Pharmaceuticals’ stock is back in the spotlight on 8 December 2025 after the company reported encouraging mid‑stage trial results for its AI‑discovered drug REC‑4881 in a rare, cancer‑linked condition called familial adenomatous polyposis. The news gives investors something they’ve been waiting on for years: early clinical proof that Recursion’s AI‑driven platform might actually work in real patients. GlobeNewswire+1
8 December 2025
···
1 … 38 39 40 41 42 … 49
Follow on Google News
Add as preferred source Open in Google News